Revolution Medicines stock hits all-time high at 193.12 USD By Investing.com

Revolution Medicines stock hits all-time high at $193.12, marking a new peak for the biotechnology firm on a strong rally. The shares were trading about 1% below its $193.09 52-week high, after climbing from a $34.00 52-week low. InvestingPro analysis cited the stock as overvalued versus its Fair Value, but also pointed to a 1-year gain of 424.05%, reflecting heightened investor confidence. In parallel, Revolution Medicines reported Phase 1/2 results for zoldonrasib at the 2026 European Society for Medical Oncology Gastrointestinal Cancers Congress, including combinations with standard chemotherapy for untreated patients and with daraxonrasib for previously treated patients. UBS raised its price target to $220 (Buy), Mizuho to $215 (Outperform), and Wedbush to $181, citing proof-of-concept for ongoing Phase 3 trials. The company also saw a block trade of 1.06 million shares worth $196.7 million.